EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM)

Matthew Strelau, Gregoire Le Gal iD, Arleigh McCurdy iD, Sudeep Shivakumar iD, Jared C Wootten iD, Maisam Abouzeenni, Chai W Phua iD, Selay Lam, Alejandro Lazo-Langner iD, Mohamed Y Abouzeenni, Martha Louzada iD

Current Oncology · 2026

DOI: 10.3390/curroncol33100633 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Current Oncology, 2026. Verfasst von Matthew Strelau und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Oncology, London Health Sciences Centre, University of Western Ontario, London, ON N6A 5W9, Canada. Hauptthemen laut MEDLINE: Aspirin, COVID-19, Lenalidomide, Multiple Myeloma. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: London Health Sciences Foundation VFCC Myeloma Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venous thromboembolism is a serious medical complication with an increased risk in patients with multiple myeloma undergoing combination treatment regimens. Acetylsalicylic acid is routinely used as a method of thromboprophylaxis in multiple myeloma patients treated with lenalidomide, and rivaroxaban has been assessed in small-scale studies in multiple myeloma patients treated with immunomodulatory drugs; yet, no study has compared the two methods. In this pilot, we asked if a full-scale trial would be feasible to assess the benefits of rivaroxaban over acetylsalicylic acid as a thromboprophylactic approach. This pilot recruited patients with multiple myeloma on lenalidomide-based therapy and randomized them to either low-dose acetylsalicylic acid or rivaroxaban, then monitored bleeding and thrombotic events throughout lenalidomide–dexamethasone treatment. A total of 55 patients were recruited across three Canadian centres, with two venous thromboembolic events and two bleeding events, all in the acetylsalicylic acid arm. We conducted a post hoc analysis of active recruitment time as a definition of recruitment feasibility, as we did not achieve our pre-defined feasibility goals. Despite the challenges in enrollment, possibly due to social restrictions during the COVID-19 pandemic, we maintain that a full-scale trial is feasible and offers insight into thromboprophylactic management in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinCOVID-19LenalidomideMultiple MyelomaRivaroxabanVenous ThromboembolismAgedFemaleHumansMaleMiddle AgedDexamethasoneFeasibility StudiesPilot ProjectsSARS-CoV-2

Stichwörter der Autor:innen

ASAanticoagulationdexamethasonelenalidomidemultiple myelomarivaroxabanthromboprophylaxisvenous thromboembolism

Substanzen

AspirinDexamethasoneLenalidomideRivaroxaban

Autor:innen und Institutionen

  • Division of Hematology, Department of Oncology, London Health Sciences Centre, University of Western Ontario, London, ON N6A 5W9, Canada.
  • Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
  • Department of Medicine, Dalhousie University, Nova Scotia Health Authority, Halifax, NS B3H 4R2, Canada.
  • Department of Epidemiology and Biostatistics, University of Western Ontario, London, ON N6A 3K7, Canada.

ORCID-Profile: Gregoire Le Gal, Arleigh McCurdy, Sudeep Shivakumar, Jared C Wootten, Chai W Phua, Alejandro Lazo-Langner, Martha Louzada

Förderung

  • London Health Sciences Foundation VFCC Myeloma Research Fund

Zitieren

APA

Strelau, M., Gal, G. L., McCurdy, A., Shivakumar, S., Wootten, J. C., Abouzeenni, M., Phua, C. W., Lam, S., Lazo-Langner, A., Abouzeenni, M. Y., & Louzada, M. (2026). Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM). Current Oncology. https://doi.org/10.3390/curroncol33100633

Vancouver

Strelau M, Gal GL, McCurdy A, Shivakumar S, Wootten JC, Abouzeenni M, et al. Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM). Current Oncology. 2026. doi:10.3390/curroncol33100633

BibTeX
@article{Strelau2026,
  author = {Strelau, Matthew and Gal, Gregoire Le and McCurdy, Arleigh and Shivakumar, Sudeep and Wootten, Jared C and Abouzeenni, Maisam and Phua, Chai W and Lam, Selay and Lazo-Langner, Alejandro and Abouzeenni, Mohamed Y and Louzada, Martha},
  title = {Challenges of Conducting a Feasibility Pilot Randomized Controlled Trial During COVID-19 Restrictions: Rivaroxaban Versus Acetyl Salicylic Acid in Patients with Multiple Myeloma on Lenalidomide-Based Therapy (RithMM)},
  journal = {Current Oncology},
  year = {2026},
  doi = {10.3390/curroncol33100633}
}
Kostenlos starten →